Skip to main content

Improving Good Practice: A Survey of Unlicensed and Off-Label Drug Use in a General Hospital in China

Therapeutic Innovation & Regulatory Science volume 47, pages 397–404 (2013)Cite this article

Abstract

Background

Off-label and unlicensed drug use is common in Europe and the US; however, information about this issue in China is limited.

Objective

To determine the scope and scale of off-label and unlicensed drug use in general hospitals in Shanghai, China, and to evaluate the varying levels of supporting evidence.

Methods

A total of 493 cases of discharge history were randomly sampled. Off-label uses were defined according to package inserts, the China Pharmacopeia Clinical Medication Notice (2010), and New Pharmacology (16th edition). All drugs administered were assessed to determine whether their use was unlicensed and off-label.

Results

There were 459 cases (93.10%) of off-label drug use, and 47.64% of total therapeutic drugs prescribed were off-label. Of these cases, 8.72% of patients received 1 off-label drug, and 9.94% of patients received 2 off-label drugs. Use of multiple off-label medications per patient was also common, and the percentage of patients receiving 3, 4, 5, 6, 7, 8, 9, and ≥10 medications was 9.74%, 9.74%, 8.72%, 7.91%, 12.58%, 7.10%, 5.88%, and 12.78%, respectively. Categories of off-label drugs used most frequently were vitamins, cardiovascular drugs, and gastroenteric drugs. The most common off-label use was that the indication for which a drug was prescribed was not approved (83.49%); other off-label uses involved disregard for contraindications and drug incompatibility (6.37%), dose exceeding approved amount (4.76%), unapproved route of administration (4.65%), and unapproved dosing intervals (0.73%). Vitamins and nutritional supplements are the drugs most frequently prescribed off-label, while off-label use of vasodilators, lipid-lowering drugs, and adjuvant therapy medications for cardiovascular and cerebrovascular conditions is also common.

Conclusion

Unlicensed and off-label prescribing of drugs may be common in China.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Jansen RM. The off-label use of medication in South Africa—what about some information for medical practitioners? S Afr Med J. 2009,99:438–439.

    PubMed  Google Scholar 

  2. Landow L. Off-label use of approved drugs. Chest. 1999;116:589–591.

    CAS  Article  Google Scholar 

  3. Gazarian M, Kelly M, McPhee JR, et al. Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust. 2006;185:544–548.

    Article  Google Scholar 

  4. Allen R, O’Brien BM. Uses of misoprostol in obstetrics and gynecology. Rev Obstet Gynecol. 2009;2:159–168.

    PubMed  PubMed Central  Google Scholar 

  5. Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. BMJ. 2000;320:79–82.

    CAS  Article  Google Scholar 

  6. ’t Jong GW, Eland IA, Sturkenboom MC, et al. Unlicensed and off-label prescription of respiratory drugs to children. Eur Respir J. 2004;23:310–313.

    Article  Google Scholar 

  7. O’Donnell CP, Stone RJ, Morley CJ. Unlicensed and off-label drug use in an Australian neonatal intensive care unit. Pediatrics. 2002;110:e52.

    Article  Google Scholar 

  8. Shah SS, Hall M, Goodman DM, et al. Off-label drug use in hospitalized children. Arch Pediatr Adolesc Med. 2007;161:282–290.

    Article  Google Scholar 

  9. Chi L, Zhang X. Survey and analysis of drug use beyond dispensatory in pediatrics. Chin J Pharmacoepidemiol. 2011;20:351–353.

    Google Scholar 

  10. Zeng X, Zhou B. Survey and analysis on a written description of the pediatric drug external use of pediatric in-patient department. China Medical Herald. 2011;8:113–114.

    Google Scholar 

  11. State Pharmacopoeia Commission. The China Pharmacopeia Clinical Medication Notice. Beijing: China Medical Science and Technology Press; 2010.

    Google Scholar 

  12. Xinqian C, Youyu J, Guang T. New Pharmacology. 16th ed. Beijing: People’s Health Publishing House; 2007.

    Google Scholar 

  13. Yi Z, Zhai S, Huang S, et al. Off-label prescriptions for adult neurological patients: a pilot survey in China. Int J Clin Pharm. 2012;34:81–87.

    Article  Google Scholar 

  14. Yang G, Wan X, Wu X. Selection of acid inhibitors for patients with critical condition. Journal of Dalian Medical University. 2010;32:441–443.

    Google Scholar 

  15. National Medical Journal of China Editorial Board. Stress ulcer prevention suggestions. National Medical Journal of China. 2002;82:1000–1001.

    Google Scholar 

  16. Sun H, Wang C, Li Y. Analysis on utilization of liver-protective medicines in our hospital during 2004–2008. China Pharmacy. 2010;21:494–496.

    Google Scholar 

  17. Xu H, Yang Y. Clinical progression on pleiotropic effects of statins. Advances in Cardiovascular Diseases. 2011;32:649–652.

    CAS  Google Scholar 

  18. Zhang J, Huang Y. Group of the China Quality Evaluation of Stroke Care and Treatment. Treatment of acute ischemic stroke in China. Chin J Neurol. 2009;42:223–228.

    Google Scholar 

  19. Cerebrovascular Disease Study Group With Acute Ischemic Stroke Treatment Guidelines Writing Group of Chinese Society of Neuropathy. Guidelines for the diagnosis and treatment of acute ischemic stroke. Chin J Neurol. 2010;43:146–153.

    Google Scholar 

  20. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42: 227–276.

    Article  Google Scholar 

  21. Zhu Y, Liu Q. Influence of Shanghai Guiding Principles of Clinical Use of Antibiotics Implementing Rules (Trial) on prophylactic use of drugs in patients underwent general surgery operation. China Pharmacy. 2010; 21:2806–2809.

    Google Scholar 

  22. Hua G, He T, Zhang Y. Clinical application of antibiotics in 2009. Chinese Journal of Nosocomiology. 2011;21:3020–3022.

    Google Scholar 

  23. Yang W, Xu Y, Sun L, et al. Compatible stabilities of insulin injection mixed with five kinds of injection in 5% glucose injection. Chinese Journal of Clinical Pharmacy. 2011;20:92–95.

    CAS  Google Scholar 

  24. Zhang C, Fan Q, Lu H, et al. Investigation the stability of compatibility of insulin in glucose and xiangdan solution for injection by HPLC. China Pharmacist. 2008;11:1299–1300.

    Google Scholar 

  25. Tian Y, Li Pa, Li C. Review of the incompatibility of traditional Chinese medicine injection in Clinical. Chinese Journal of Pharmacovigilance. 2010;7:105–108.

    Google Scholar 

  26. Rowland D, McMahon CG, Abdo C, et al. Disorders of orgasm and ejaculation in men. J Sex Med. 2010;7:1668–1686.

    Article  Google Scholar 

  27. Zhang Y, Liu S, Zhu G, et al. Clinical study of Sildenafil for the treatment of pulmonary hypertension. Journal of Cardiovascular and Pulmonary Diseases. 2011;30:20–24.

    Google Scholar 

  28. Liao G. Exploration of the management of antibiotics use in the clinic. China Pharmacy. 2011;22:2406–2408.

    Google Scholar 

  29. Xu R, Zhang S, Chen J. Suggestion and pondering for the registration system of medical representatives. China Pharmacy. 2007;18:241–243.

    Google Scholar 

  30. Zheng J. Doctors’ incentive and separation mechanism design. Chinese Hospitals. 2010;14:42–45.

    Google Scholar 

  31. Zhou Y, Li K, Huang J, et al. Analysis on unharmonious factors influencing hospital and patient relationship and their countermeasures. Chinese Hospitals. 2011;15:58–61.

    Google Scholar 

  32. Largent EA, Miller FG, Pearson SD. Going off-label without venturing off-course: evidence and ethical off-label prescribing. Arch Intern Med. 2009;169:1745–1747.

    Article  Google Scholar 

  33. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166:1021–1026.

    Article  Google Scholar 

  34. Jansen RM, Gouws C. Clinical, legal and ethical implications of the intra-ocular (off-label) use of bevacizumab (Avastin)—a South African perspective. S Afr Med J. 2009;99:446–449.

    PubMed  Google Scholar 

  35. Largent EA, Miller FG, Pearson SD. Going off-label without venturing off-course: evidence and ethical off-label prescribing. Arch Intern Med. 2009;169:1745–1747.

    Article  Google Scholar 

  36. Stafford RS. Regulating off-label drug use—rethinking the role of the FDA. N Engl J Med. 2008;358:1427–1429.

    CAS  Article  Google Scholar 

  37. People’s Republic of China, Ministry of Health. The Ministry of Health Prescription Management Policy, May 1, 2007 [in Chinese]. http://www.gov.cn/flfg/2007-03/13/content_549406.htm.

  38. People’s Republic of China, Ministry of Health. Hospital Prescription Comment Management Practices (Trial), February 10, 2010 [in Chinese]. http://www.gov.cn/gzdt/2010-03/04/content_1547080.htm.

  39. Chen X, Huang Z, Hou L, et al. Expert consensus document on drug off-label use. Pharmacy Today. 2010;20:1–3.

    CAS  Google Scholar 

  40. Toscani F, Di Giulio P, Campi R, et al. Off-label prescriptions in Italian hospices: a national survey. J Pain Symptom Manage. 2009;38:365–371.

    Article  Google Scholar 

  41. Largent EA, Miller FG, Pearson SD. Going off-label without venturing off-course: evidence and ethical off-label prescribing. Arch Intern Med. 2009;169:1745–1747.

    Article  Google Scholar 

Download references

Author information

Affiliations

  1. Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China

    Hanbin Wu MMS

  2. Department of Pharmacy, The 411st Hospital of PLA, Shanghai, 200081, China

    Gao Wu MMS

Authors
  1. Hanbin Wu MMS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gao Wu MMS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hanbin Wu MMS.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Wu, H., Wu, G. Improving Good Practice: A Survey of Unlicensed and Off-Label Drug Use in a General Hospital in China. Ther Innov Regul Sci 47, 397–404 (2013). https://doi.org/10.1177/2168479013491753

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/2168479013491753

Keywords

  • China
  • off-label drug use
  • unlicensed drug
  • general hospital